Thr74
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Thr74  -  C/EBP-epsilon (human)

Site Information
RGLKGPGtPAFPHyL   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 455780

In vivo Characterization
Methods used to characterize site in vivo:
[32P] bio-synthetic labeling ( 8 ) , immunoprecipitation ( 7 ) , mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 ) , mutation of modification site ( 7 ) , phosphoamino acid analysis ( 8 ) , western blotting ( 7 )
Relevant cell line - cell type - tissue:

Downstream Regulation
Effects of modification on C/EBP-epsilon:
molecular association, regulation ( 7 )
Effects of modification on biological processes:
cell differentiation, altered ( 7 ) , transcription, induced ( 7 , 8 )
Induce interaction with:
DNA ( 7 ) , NFkB-p65 (human) ( 7 )

References 

1

Mulhern D (2012) CST Curation Set: 13339; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

2

Mulhern D (2012) CST Curation Set: 13340; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

3

Mulhern D (2011) CST Curation Set: 12551; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

4

Guo A (2011) CST Curation Set: 12018; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

5

Guo A (2011) CST Curation Set: 12020; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

6

Guo A (2011) CST Curation Set: 12022; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

7

Chumakov AM, Silla A, Williamson EA, Koeffler HP (2007) Modulation of DNA binding properties of CCAAT/enhancer binding protein epsilon by heterodimer formation and interactions with NFkappaB pathway. Blood 109, 4209-19
17255362   Curated Info

8

Williamson EA, et al. (2005) CCAAT/enhancer binding protein epsilon: changes in function upon phosphorylation by p38 MAP kinase. Blood 105, 3841-7
15677566   Curated Info